{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:05:49Z","timestamp":1774497949518,"version":"3.50.1"},"reference-count":11,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"DOI":"10.1182\/blood.2019003395","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T21:49:33Z","timestamp":1579038573000},"page":"766-769","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Molecular monitoring\u00a0during\u00a0dose reduction predicts recurrence after TKI cessation in CML"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-9601","authenticated-orcid":false,"given":"Andrea","family":"Gottschalk","sequence":"first","affiliation":[{"name":"Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit\u00e4t Dresden, Dresden, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2524-1199","authenticated-orcid":false,"given":"Ingmar","family":"Glauche","sequence":"first","affiliation":[{"name":"Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit\u00e4t Dresden, Dresden, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-6203","authenticated-orcid":false,"given":"Silvia","family":"Cicconi","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1261-3299","authenticated-orcid":false,"given":"Richard E.","family":"Clark","sequence":"first","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-0608","authenticated-orcid":false,"given":"Ingo","family":"Roeder","sequence":"first","affiliation":[{"name":"Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit\u00e4t Dresden, Dresden, Germany;"},{"name":"National Center for Tumor Diseases, Partner Site Dresden, Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"9976","key":"2020030512010342500_B1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"2020030512010342500_B2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am J Hematol"},{"issue":"24","key":"2020030512010342500_B3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020030512010342500_B4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-016-2839-z","article-title":"Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response","volume":"96","author":"Cervantes","year":"2017","journal-title":"Ann Hematol"},{"issue":"11","key":"2020030512010342500_B5","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","article-title":"Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data","volume":"103","author":"Fassoni","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"2020030512010342500_B6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2020030512010342500_B7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-free remission with first- and second-generation tyrosine kinase inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"2020030512010342500_B8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020030512010342500_B9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020030512010342500_B10","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"2020030512010342500_B11","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/10\/766\/1717878\/bloodbld2019003395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/10\/766\/1717878\/bloodbld2019003395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T03:29:43Z","timestamp":1695612583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/10\/766\/431016\/Molecular-monitoringduringdose-reduction-predicts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,3,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003395","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}